Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
Ardelyx (NASDAQ: ARDX) announced a post-hoc analysis presentation of the OPTIMIZE Study for XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings in Boston. The study analyzed 330 patients with chronic kidney disease on dialysis with hyperphosphatemia.
XPHOZAH, the first FDA-approved phosphate absorption inhibitor (PAI), is designed to reduce serum phosphorus in adult CKD patients on dialysis as add-on therapy. The analysis revealed that among 40% of patients reporting diarrhea, those using loperamide had lower discontinuation rates (9.7%) compared to non-users (24.6%).
The company is also hosting an Exhibitor Showcase on April 11, 2025, focusing on hyperphosphatemia management, where Dr. Vincent Carsillo will discuss XPHOZAH's mechanism of action, efficacy, and safety data from Phase 3 trials.
Ardelyx (NASDAQ: ARDX) ha annunciato una presentazione di analisi post-hoc dello Studio OPTIMIZE per XPHOZAH® (tenapanor) durante le Riunioni Cliniche Primaverili della National Kidney Foundation a Boston. Lo studio ha analizzato 330 pazienti con malattia renale cronica in dialisi con iperfosfatemia.
XPHOZAH, il primo inibitore dell'assorbimento del fosfato (PAI) approvato dalla FDA, è progettato per ridurre il fosforo sierico nei pazienti adulti con CKD in dialisi come terapia aggiuntiva. L'analisi ha rivelato che tra il 40% dei pazienti che riportavano diarrea, coloro che utilizzavano loperamide avevano tassi di interruzione più bassi (9,7%) rispetto ai non utilizzatori (24,6%).
L'azienda ospiterà anche un Esposizione degli Espositori l'11 aprile 2025, focalizzandosi sulla gestione dell'iperfosfatemia, dove il Dr. Vincent Carsillo discuterà il meccanismo d'azione di XPHOZAH, l'efficacia e i dati di sicurezza provenienti dagli studi di Fase 3.
Ardelyx (NASDAQ: ARDX) anunció una presentación de análisis post-hoc del Estudio OPTIMIZE para XPHOZAH® (tenapanor) en las Reuniones Clínicas de Primavera de la National Kidney Foundation en Boston. El estudio analizó a 330 pacientes con enfermedad renal crónica en diálisis con hiperfosfatemia.
XPHOZAH, el primer inhibidor de absorción de fosfato (PAI) aprobado por la FDA, está diseñado para reducir el fósforo sérico en pacientes adultos con ERC en diálisis como terapia adicional. El análisis reveló que entre el 40% de los pacientes que informaron diarrea, aquellos que usaban loperamida tenían tasas de interrupción más bajas (9.7%) en comparación con los no usuarios (24.6%).
La empresa también organizará una Exposición de Expositores el 11 de abril de 2025, centrada en la gestión de la hiperfosfatemia, donde el Dr. Vincent Carsillo discutirá el mecanismo de acción de XPHOZAH, su eficacia y los datos de seguridad de los ensayos de Fase 3.
Ardelyx (NASDAQ: ARDX)는 보스턴에서 열린 National Kidney Foundation 봄 임상 회의에서 XPHOZAH® (tenapanor)에 대한 OPTIMIZE 연구의 사후 분석 발표를 발표했습니다. 이 연구는 고인산혈증을 앓고 있는 투석 환자 330명을 분석했습니다.
XPHOZAH는 FDA에서 승인한 최초의 인산 흡수 억제제(PAI)로, 투석 중인 성인 만성 신장 질환(CKD) 환자의 혈청 인산을 줄이기 위해 설계된 보조 요법입니다. 분석 결과, 설사를 보고한 환자 중 40%에서 로페라마이드를 사용하는 환자들은 비사용자(24.6%)에 비해 중단율이 낮은 것으로 나타났습니다(9.7%).
회사는 또한 2025년 4월 11일에 고인산혈증 관리를 주제로 한 전시회를 개최하며, 이 자리에서 Vincent Carsillo 박사가 XPHOZAH의 작용 메커니즘, 효능 및 3상 시험의 안전성 데이터를 논의할 것입니다.
Ardelyx (NASDAQ: ARDX) a annoncé une présentation d'analyse post-hoc de l'étude OPTIMIZE pour XPHOZAH® (tenapanor) lors des réunions cliniques de printemps de la National Kidney Foundation à Boston. L'étude a analysé 330 patients atteints de maladie rénale chronique sous dialyse avec hyperphosphatémie.
XPHOZAH, le premier inhibiteur de l'absorption du phosphate (PAI) approuvé par la FDA, est conçu pour réduire le phosphore sérique chez les patients adultes atteints de CKD sous dialyse en tant que thérapie complémentaire. L'analyse a révélé que parmi les 40 % de patients rapportant de la diarrhée, ceux utilisant de la lopéramide avaient des taux d'abandon plus faibles (9,7 %) par rapport aux non-utilisateurs (24,6 %).
L'entreprise organise également une vitrine d'exposants le 11 avril 2025, axée sur la gestion de l'hyperphosphatémie, où le Dr Vincent Carsillo discutera du mécanisme d'action de XPHOZAH, de son efficacité et des données de sécurité des essais de phase 3.
Ardelyx (NASDAQ: ARDX) gab eine Präsentation einer post-hoc Analyse der OPTIMIZE-Studie für XPHOZAH® (tenapanor) während der Frühjahrsklinikveranstaltungen der National Kidney Foundation in Boston bekannt. Die Studie analysierte 330 Patienten mit chronischer Nierenerkrankung, die aufgrund von Hyperphosphatämie dialysiert wurden.
XPHOZAH, der erste von der FDA zugelassene Inhibitor der Phosphatabsorption (PAI), ist darauf ausgelegt, den Serumphosphor bei erwachsenen CKD-Patienten in der Dialyse als Zusatztherapie zu reduzieren. Die Analyse zeigte, dass unter den 40% der Patienten, die über Durchfall berichteten, diejenigen, die Loperamid einnahmen, niedrigere Abbruchraten (9,7%) im Vergleich zu Nichtnutzern (24,6%) hatten.
Das Unternehmen veranstaltet auch eine Ausstellerpräsentation am 11. April 2025, die sich auf das Management von Hyperphosphatämie konzentriert, bei der Dr. Vincent Carsillo den Wirkmechanismus von XPHOZAH, die Wirksamkeit und die Sicherheitsdaten aus Phase-3-Studien erörtern wird.
- First and only FDA-approved phosphate absorption inhibitor (PAI) in its class
- Lower discontinuation rates (9.7% vs 24.6%) when using antidiarrheal medication
- Simple dosing regimen of one tablet twice daily
- 40% of patients reported diarrhea as a side effect
- 24.6% discontinuation rate due to diarrhea in patients not using antidiarrheal medication
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.
XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.
OPTIMIZE was a randomized, open label study which included 330 patients with chronic kidney disease (CKD) on dialysis with hyperphosphatemia. The study was designed to evaluate different methods of optimizing phosphorus management with XPHOZAH in both binder-naïve and binder-treated patients.
“Now more than one year since the launch of XPHOZAH, we are seeing that patients are receiving the benefits of the treatment and experiencing improved phosphate control,” said David Spiegel, MD, senior vice president, nephrology at Ardelyx. “At the same time, we recognize how important it is to continue to understand the patient experience and provide insights in how to help patients have a positive experience with the therapy to support adherence to treatment and achieve target phosphate goals. Analyses, like the one presented at NKF Spring Clinical Meetings, provide insight into methods that healthcare providers can use to optimize treatment with XPHOZAH. In this case, it was observed that among patients experiencing loose stools on XPHOZAH, those who used an anti-diarrheal medication had a lower rate of treatment discontinuation due to diarrhea.”
Poster #G-310, entitled “Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Saw Decreased Stool Frequency and Improved Stool Consistency,” is a post hoc analysis of the OPTIMIZE study and evaluated discontinuation rates and changes in stool frequency and consistency in patients receiving tenapanor who self-medicated with the over-the-counter antidiarrheal agent loperamide. The analysis found that among the
Poster presentations are now publicly available and can be accessed on demand here.
In addition to the poster presentation during NKF Spring Clinical Meetings, Ardelyx is sponsoring an Exhibitor Showcase titled: “A Different Perspective on Hyperphosphatemia Management: Evaluating Current Strategies” on April 11, 2025, from 12:00-12:35 PM EDT, where Dr. Vincent Carsillo, will discuss first-in-class PAI, XPHOZAH. The presentation will review the XPHOZAH mechanism of action, efficacy and safety data from the Phase 3 clinical trial program and will include a discussion about the clinical application of XPHOZAH as add-on therapy for the many dialysis patients on a phosphate binder with serum phosphorus levels above guideline-established targets.
About XPHOZAH® (tenapanor)
XPHOZAH, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), thereby reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption. XPHOZAH is a single tablet, taken twice daily. Diarrhea was the most common side effect experienced by patients taking XPHOZAH in clinical trials. Please see additional full Prescribing Information.
About Hyperphosphatemia
Hyperphosphatemia is a serious condition, defined as elevated levels of phosphate in the blood, which affects the vast majority of the 550,000 patients in the United States with chronic kidney disease (CKD) on maintenance dialysis. The kidneys are responsible for eliminating excess phosphate and as kidney function declines, phosphate is not adequately eliminated from the body. As a result, hyperphosphatemia is a nearly universal condition among people with CKD on maintenance dialysis, with internationally recognized KDIGO treatment guidelines that recommend lowering elevated phosphate levels toward the normal range (2.5-4.5mg/dL).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
XPHOZAH is contraindicated in:
- Pediatric patients under 6 years of age
- Patients with known or suspected mechanical gastrointestinal obstruction
WARNINGS AND PRECAUTIONS
Diarrhea
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
MOST COMMON ADVERSE REACTIONS
Diarrhea, which occurred in 43
INDICATION
XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
For additional safety information, please see full Prescribing Information.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Lindsey Manuel
lmanuel@ardelyx.com
FAQ
What were the key findings of ARDX's OPTIMIZE Study post-hoc analysis for XPHOZAH?
How is XPHOZAH administered to CKD patients on dialysis?
What is the primary indication for XPHOZAH according to FDA approval?
How many patients participated in the ARDX OPTIMIZE Study for XPHOZAH?
